Month: January 2024

Panostaja Oyj    Stock Exchange Bulletin, Insider Information   January 23, 2024    11.00 a.mPanostaja’s investment target Grano starts change negotiations Panostaja Plc’s investment target Grano will start change negotiations targeting all Grano Group personnel, excluding its subsidiary Grano Diesel. Change negotiations will be initiated to improve the company’s profitability and strengthen the company’s long-term competitiveness. The planned structural and organisational changes and other cost-saving measures are estimated to result in annual cost savings of approximately EUR 4.5 million. The savings targets are expected to be fully realised in the financial year 2025. If the plans are implemented, they may lead to the termination of employment contracts of a maximum of 84 employees, changes in the terms of...

An important part of HEALWELL’s forward growth and value creation strategy involves acquiring, investing in and/or partnering with data focused companies such as electronic medical record (“EMR”), electronic health record (“EHR”), patient flow and/or other similar businesses and integrating our Artificial Intelligence (“AI”) technologies that will provide next-generation AI-powered clinical decision support capabilities and new revenue streams. These technologies will provide patients and physicians with powerful tools to drive better health outcomes at lower costs in a manner aligned with global Value Based Care (“VBC”) trends. HEALWELL subsidiary KHURE HEALTH has re-engaged its Clinical Decision Support (CDS) commercial roadmap with life sciences and pharmaceutical companies resulting in fresh commercial wins, repeat/extended projects,...

INVL Financial Advisors, a brokerage firm belonging to Invalda INVL, the leading asset management group in the Baltics, acting under the brand INVL Family Office, has established a branch in Latvia to provide investment services. INVL Financial Advisors launches its operations in Latvia after the approval of the Latvian financial markets supervisory authority. “Until now, the investment services provided by INVL Family Office have been available to natural persons and legal entities residing in Lithuania. The authorisation to provide services in Latvia will allow us to establish ourselves in this market and to provide wealthy families with exceptional investment solutions that will help achieve and maintain financial freedom for several generations to come,” says Asta Jovaišienė, Head of INVL Family Office. INVL Financial Advisors,...

Company announcement no. 05 In company announcement no. 8 2023, Spar Nord announced a share buyback programme of up to DKK 300 million. The share buyback was initiated on 13 February 2023. The purpose of the share buyback is to reduce the bank’s share capital by the shares acquired under the programme, and the programme is executed pursuant to Regulation (EU) No 596/2014 of 16 April 2014 (“Market Abuse Regulation”). In week 03 the following transactions were made under the share buyback programme.  Number of shares Average purchase price Transaction value (DKK)Accumulated from last announcement 2,714,100   294,251,76915 January 2024 1,500 113.28 169,92016 January 2024 2,000 110.98 221,96017 January 2024 3,000 108.55 325,65018 January 2024 3,000 109.22 327,66019 January 2024 3,000 109.55 328,650Total week...

Lassila & Tikanoja plc Investor News 23 January 2024 9.00 am Lassila & Tikanoja plc will publish Financial Statements release for 2023 on 9 February 2024 Lassila & Tikanoja plc will publish Financial Statements release for 2023 on Friday 9 February 2024 at 8.00 am. After publication, the release will be available on the company’s website at www.lt.fi/en. Lassila & Tikanoja will host a conference call and webcast for analysts, institutional investors and media on 9 February 2024 at 10.30 am Finnish time. The presentation material will be published on the company’s website. The English language briefing will be hosted by CEO Eero Hautaniemi and CFO Valtteri Palin. Conference call You can access the teleconference by registering on the link below. After the registration you will be provided phone numbers and...

Successful completion of contractual site acceptance tests, with 70 MeV cyclotron now fully operational  Louvain-la-Neuve, Belgium, January 23, 2024 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, is pleased to announce that the Cyclone® 70 system installed at the iThemba Laboratory for Accelerator Based Sciences (iThemba LABS) in Cape Town, one of the research facilities of the National Research Foundation of South Africa, has been fully commissioned enabling iThemba LABS to start transferring the production of radioisotopes from their existing accelerator to the new Cyclone® 70 system. Acceptance testing was completed in December 2023, with the cyclotron reaching full beam power (750µA) at full energy. This...

PRESS RELEASE – INSIDE INFORMATION Following a post-hoc analysis of a Phase 3 trial demonstrating pain relief in patients with severe knee osteoarthritis, Biosenic applied for an international patent to support the newly focused indication of JTA-004. Mont-Saint-Guibert, Belgium, January 23, 2024, 7.00am CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company focused on serious autoimmune and inflammatory diseases and cell therapy, today announces the filing of a U.S. patent for JTA-004, a viscosupplement in late-stage clinical development, following new evidence of its efficacy in a recently defined subtype of osteoarthritis (OA). There are several types of OA. In 2022, outside investigators publishedi findings that defined three subtypes based on biomarkers – including a severe form marked by high levels of...

NEW YORK, NY, Jan. 22, 2024 (GLOBE NEWSWIRE) — Newcourt Acquisition Corp (“Newcourt”) (NASDAQ: NCAC) announced today that the conditions to closing the business combination (the “Business Combination”) pursuant to the Amended and Restated Business Combination Agreement, dated July 31, 2023 (as amended, supplemented, or otherwise modified from time to time, the “Amended and Restated Business Combination Agreement”), by and among Newcourt, Newcourt SPAC Sponsor LLC, Psyence Group Inc. (CSE: PSYG) (“Psyence”), Psyence Biomedical Ltd., a corporation organized under the laws of Ontario, Canada (“Pubco”), Psyence (Cayman) Merger Sub, Psyence Biomed Corp., and Psyence Biomed II Corp. have not yet been satisfied and the business combination has not closed. The parties are working together to expeditiously satisfy such closing conditions,...